GlassScriptPhysician profile
Steven A Haskel
NPI 1639163561
$421.97
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.18 · 2021: $355.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $300.00 | 2021 | |
| Abbvie INC. | $28.41 | 2019-2021 | |
| Glaxosmithkline, LLC. | $27.44 | 2019 | |
| Myovant Sciences INC. | $15.00 | 2021 | |
| Exeltis, USA INC. | $13.42 | 2021 | |
| Allergan, INC. | $13.00 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.77 | 2019 | |
| Mayne Pharma Commercial LLC | $11.93 | 2021 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Haskel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.